Codiak BioSciences to Participate in Upcoming BTIG and Wedbush PacGrow Investor Conferences
03 août 2022 16h15 HE
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a...
Codiak BioSciences to Participate at William Blair Biotech Focus Conference 2022
11 juil. 2022 09h44 HE
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., July 11, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a...
CEPI and Codiak BioSciences partner to develop broadly protective Betacoronavirus vaccine
05 juil. 2022 06h30 HE
|
Codiak BioSciences, Inc.
OSLO, Norway and CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- CEPI, the Coalition for Epidemic Preparedness Innovations, and Codiak BioSciences (NASDAQ: CDAK) today announced the latest...
Codiak Provides Platform-Validating Clinical Update and Data from Phase 1 Trials of exoSTING™ and exoIL-12™
30 juin 2022 06h30 HE
|
Codiak BioSciences, Inc.
– Codiak’s engineered exosome candidates demonstrate potential for best-in-class profile, with tumor retention and delivery to the cells of interest allowing for increased therapeutic window – –...
Codiak Initiates Patient Dosing in Phase 1 Clinical Trial of exoASO™-STAT6 in Patients with Advanced Hepatocellular Carcinoma, Liver Metastases from Primary Gastric Cancer and Colorectal Cancer
29 juin 2022 08h00 HE
|
Codiak BioSciences, Inc.
exoASO-STAT6 is the third engineered exosome candidate generated from Codiak’s engEx® Platform to enter clinical development CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Codiak...
Codiak Presents New Preclinical Data at ASGCT 2022 on Exosome-Based Strategy to Enhance AAV Gene Therapy
17 mai 2022 07h00 HE
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a...
Codiak BioSciences Reports First Quarter 2022 Financial Results and Operational Progress
05 mai 2022 16h01 HE
|
Codiak BioSciences, Inc.
– Codiak to provide data from ongoing exoSTING™ and exoIL-12™ clinical trials in late 1H 2022 – – Anticipate first patients dosed in exoASO™-STAT6 Phase 1 clinical trial in 1H 2022 – – Data from...
Codiak Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer
02 mai 2022 09h00 HE
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a...
Codiak Presents New Preclinical Data Supporting Development of a Broadly Protective Pan Beta-Coronavirus Vaccine
20 avr. 2022 16h40 HE
|
Codiak BioSciences, Inc.
– Engineered exosome vaccine construct generated durable, comprehensive immunity in vivo – CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a...
Codiak’s exoASO™-C/EBPβ Demonstrates Significant Systemic Anti-Tumor Activity via Targeting Immune-Suppressive Myeloid Cells
08 avr. 2022 13h00 HE
|
Codiak BioSciences, Inc.
– New preclinical data presented at AACR Annual Meeting 2022 – – Intravenous exosome candidate engineered for tropism precisely targets transcription factors in myeloid cell subpopulations – –...